Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Merck advises against changing Gardasil's approved dosing regimen despite studies suggesting single-dose efficacy. Read more ...

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Merck (NYSE:MRK) recently announced a third-quarter dividend affirmation of $0.81 per share, underscoring its commitment to returning value to shareholders. Over the past week, the company's stock ...

Merck’s MRK shares have lost 21.3% so far this year compared with a decrease of 4.5% for the industry. The stock has also ...